Telemedicine and Digital Health in Psoriasis

The convergence of telemedicine platforms, smartphone applications, and artificial intelligence is creating new models for psoriasis management that extend care beyond the traditional clinic visit. The COVID-19 pandemic (Section 30) accelerated adoption of remote care, and emerging evidence suggests these approaches may become permanent features of dermatological practice.

29.1 Teledermatology for Psoriasis

The International Psoriasis Council (IPC) has endorsed remote monitoring as a feasible alternative to in-person visits for established psoriasis patients, and the National Psoriasis Foundation (NPF) published 22 consensus statements on telemedicine in psoriasis management (JMIR, 2025).

Two models of teledermatology are in use:

Store-and-forward (asynchronous): Patients submit photographs and clinical information through a secure platform; a dermatologist reviews and responds within hours to days. This model works well for routine monitoring of stable disease and medication refills.
Live video (synchronous): Real-time consultations via video link. Preferred for initial assessments, treatment decisions, and patient education.

Evidence for effectiveness is nuanced:

Specialist-led remote care works: studies demonstrate comparable clinical outcomes (PASI improvement, DLQI change) between teledermatology and face-to-face consultations for established psoriasis patients on stable therapy.
Primary care-led remote management shows non-significant outcomes, highlighting the importance of specialist expertise in interpreting clinical images and making treatment decisions (Frontiers in Digital Health, 2025).

Limitations include difficulty assessing palpable features (induration, tenderness), challenges with image quality and standardisation, potential for missed diagnoses (particularly in darker skin phototypes where erythema is less visible in photographs, see Section 21.3), and digital literacy barriers in older or socioeconomically disadvantaged populations.

Research stage: Established. Evidence strength: Moderate-High. Consensus guidelines published; RCTs supporting specialist-led remote care.

29.2 Mobile Health Applications

A growing ecosystem of smartphone apps supports psoriasis self-management:

Symptom tracking: Apps that let you photograph lesions over time, track PASI or BSA, and record flare triggers. Longitudinal self-monitoring data can inform clinical decisions and help you identify personal trigger patterns.
Education and community: Platforms connecting patients with evidence-based information and peer support networks (complementing the organisations listed in Appendix A2).
Treatment adherence: Medication reminder apps that prompt topical application or injection scheduling. Given that non-adherence to topical therapy is one of the primary drivers of treatment failure (Section 23), these tools address a real clinical challenge.

Psorcast is a notable research application developed to collect real-world data on psoriasis and PsA. It uses smartphone sensors and patient-reported outcomes to predict PsA flares and assess medication efficacy in real-world settings.

Limitations include variable app quality, lack of regulatory oversight (most health apps aren’t classified as medical devices), privacy concerns regarding health data, and the “digital divide” — patients most in need of support may have least access to smartphone technology.

Research stage: Emerging. Evidence strength: Low-Moderate. Pilot studies and feasibility trials; few RCTs comparing app-based interventions with standard care.

29.3 AI-Integrated Diagnostics

Section 28.7 describes the application of AI to PASI scoring and lesion detection. In the context of digital health, AI integration extends to point-of-care diagnostic tools:

An EfficientNet-B4 deep learning model achieved 92.3% accuracy in differentiating psoriasis from other papulosquamous disorders (seborrhoeic dermatitis, pityriasis rosea, lichen planus) using dermoscopic images, outperforming several non-specialist dermatologists.
AI-powered tools integrated into teledermatology platforms could enable automated severity scoring, reducing inter-rater variability and increasing consistency of remote assessments.
Subtype identification: Machine learning models are being trained to distinguish between psoriasis subtypes (plaque, guttate, pustular) from clinical photographs, which could support diagnostic accuracy in primary care settings.

Critical challenges remain:

Skin phototype diversity: Most training datasets are dominated by images of lighter skin, potentially reducing accuracy in darker skin phototypes and exacerbating existing diagnostic disparities (Section 21.3).
Standardisation: Inconsistent imaging protocols (lighting, resolution, distance) across clinical settings reduce model reliability.
Regulatory frameworks: AI-assisted clinical decision-making tools face evolving regulatory requirements that vary by jurisdiction.

Research stage: Emerging. Evidence strength: Moderate. Validation studies with strong accuracy metrics; real-world deployment limited; diversity and standardisation remain barriers.

29.4 Remote Monitoring and Treatment Optimisation

Looking further ahead, digital health may enable continuous, passive monitoring of psoriasis:

Wearable devices: Sensors measuring skin temperature, moisture, and scratching behaviour (accelerometry) could detect subclinical flares before they become visible, enabling pre-emptive treatment adjustment.
Patient-reported outcome (PRO) platforms: Structured digital collection of DLQI, itch VAS (visual analogue scale), and pain scores between clinic visits, feeding directly into electronic health records.
Biologic dosing optimisation: Integration of remote severity data with pharmacokinetic modelling could support personalised dosing intervals. For example, extending IL-23 inhibitor dosing in patients maintaining PASI 0 or reducing intervals in patients showing early signs of relapse.

These approaches are conceptual or in early pilot stages, but they represent the trajectory of psoriasis care: from episodic, clinic-based assessment to continuous, data-driven management.

Research stage: Experimental. Evidence strength: Low. Concept papers and pilot feasibility studies; no established clinical protocols.